Evidence brief
BPC-157: Research evidence and Canadian regulatory context
This educational profile separates preclinical observations from the limited human literature. It does not provide a treatment, administration, dosing, sourcing, or product-quality recommendation.
Evidence maturity: limited human literature; preclinical work dominates.
Human evidence
A 2025 scoping review describes the available human literature as extremely limited and calls for well-designed trials. Its discussion of small pilot observations does not establish efficacy, safety, or clinical utility.
Preclinical context
Published reviews describe tissue and vascular observations across cellular and animal models. Those findings are hypothesis-generating context; they cannot be assumed to predict outcomes in people.
What remains unknown
Large, controlled human studies, standardized product information, reliable safety characterization, and validated clinical indications remain absent from the cited evidence base.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| limited human literature; preclinical work dominates. | A 2025 scoping review describes the available human literature as extremely limited and calls for well-designed trials. Its discussion of small pilot observations does not establish efficacy, safety, or clinical utility. | Large, controlled human studies, standardized product information, reliable safety characterization, and validated clinical indications remain absent from the cited evidence base. |
Canadian regulatory context
Health Canada’s public advisory discusses risks associated with unauthorized injectable peptide drugs and directs Canadians to authorized-product and licensed-pharmacy resources. The advisory is not an endorsement of any product or use.
Evidence timeline
- 1
Preclinical literature: tissue and vascular research questions
- 2
2025: scoping review synthesizes limited human literature
- 3
Current: controlled human outcome and long-term safety gaps remain
How to read this evidence brief
Population first
Start with the studied population and protocol before interpreting an outcome. A result in a defined disease group does not automatically generalize to other readers.
Outcome second
Separate measured endpoints from broader claims about health, performance, product quality, or long-term benefit.
Limitations remain visible
The evidence gaps and regulatory context are part of the record, not footnotes to be ignored.
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- BPC-157 scoping review (2025)
Review of preclinical findings and limited human evidence.
- Health Canada public advisory
Official Canadian information on unauthorized injectable peptide drugs.